Copyright
©The Author(s) 2020.
World J Clin Oncol. May 24, 2020; 11(5): 275-282
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.275
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.275
Table 2 Non-amino acid buffer systems frequently used in antibody parenteral products
| Buffer system | Controlled pH range (25 °C) | Acid | Base | Example product |
| Phosphate | 5.8-7.8 | Monosodium phosphate | Disodium phosphate | Tysabri® |
| Acetate | 3.8-5.8 | Acetic acid | Sodium acetate | Amgevita® |
| Citrate | 3.0-7.4 | Citric acid | Sodium citrate | Humira® |
| Succinate | 3.3-6.6 | Succinic acid | Sodium succinate | Kadcyla® |
| Tris | 7-9 | Tris-HCl | Tris | Besponsa® |
- Citation: Zhang Y, Williams III RO, Tucker HO. Formulation strategies in immunotherapeutic pharmaceutical products. World J Clin Oncol 2020; 11(5): 275-282
- URL: https://www.wjgnet.com/2218-4333/full/v11/i5/275.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i5.275